Financial Analysts Roundtable: The Safety Climate, Portfolio Management, And More Restructuring In 2005
Executive Summary
Three large-cap pharmaceutical analysts sat down with "The Pink Sheet" in January to discuss the future of the drug industry. Below are excepts from a conversation with Goldman Sachs' Jim Kelly, Morgan Stanley's Jami Rubin and Deutsche Bank's Barbara Ryan
You may also be interested in...
Waiting For Pfizer: GSK Will Cut Sales Force Should Pfizer Act First
GlaxoSmithKline will reduce the size of its sales force and reinvest those expenditures in research and development should Pfizer decide to downsize its sales team, GSK CEO J.P. Garnier said
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?